{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:32:11Z","timestamp":1786116731855,"version":"build-2736575974"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"crossref","award":["78181"],"award-info":[{"award-number":["78181"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12519-x","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:48:14Z","timestamp":1786013294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mitochondrial metabolism and PD-1 blockade: mechanisms and therapeutic opportunities in cancer immunotherapy"],"prefix":"10.1007","volume":"53","author":[{"given":"Khadijeh","family":"Dizaji Asl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Kalarestaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Rafat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadmahdi","family":"Bahramloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Alinejad Shahabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasti","family":"Shakouri Mollayousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyede Sepide Ashraf","family":"Moosavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2298-0228","authenticated-orcid":false,"given":"Zeinab","family":"Mazloumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"12519_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s43046-025-00319-6","volume":"37","author":"M Devaraji","year":"2025","unstructured":"Devaraji M, Varghese Cheriyan B (2025) Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions. J Egypt Natl Cancer Inst 37:62","journal-title":"J Egypt Natl Cancer Inst"},{"issue":"21","key":"12519_CR2","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.3390\/jcm13216537","volume":"13","author":"P Garg","year":"2024","unstructured":"Garg P, Pareek S, Kulkarni P, Horne D, Salgia R, Singhal SS (2024) Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment. J Clin Med 13(21):6537","journal-title":"J Clin Med"},{"key":"12519_CR3","doi-asserted-by":"publisher","first-page":"1140977","DOI":"10.3389\/fmmed.2023.1140977","volume":"3","author":"F Hamdan","year":"2023","unstructured":"Hamdan F, Cerullo V (2023) Cancer immunotherapies: A hope for the uncurable? Front Mol Med 3:1140977","journal-title":"Front Mol Med"},{"key":"12519_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","volume":"24","author":"M Zhang","year":"2025","unstructured":"Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh M, Nabavi N et al (2025) Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer 24:136","journal-title":"Mol Cancer"},{"key":"12519_CR5","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s11033-026-12017-0","volume":"53","author":"A \u00d6nal","year":"2026","unstructured":"\u00d6nal A, Ayaz F, Aydemir E (2026) Cancer immunotherapy: mechanisms, clinical applications, resistance and future directions. Mol Biol Rep 53:831","journal-title":"Mol Biol Rep"},{"key":"12519_CR6","doi-asserted-by":"publisher","first-page":"e20634","DOI":"10.1002\/advs.202520634","volume":"13","author":"Y Yu","year":"2026","unstructured":"Yu Y, Yao X, Wang Q, Yang M, Li R, Qin J et al (2026) T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities. Adv Sci 13:e20634","journal-title":"Adv Sci"},{"issue":"8","key":"12519_CR7","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP (2023) Immune checkpoint therapy-current perspectives and future directions. Cell 186(8):1652\u20131669","journal-title":"Cell"},{"key":"12519_CR8","doi-asserted-by":"publisher","first-page":"1680838","DOI":"10.3389\/fimmu.2025.1680838","volume":"16","author":"J Park","year":"2025","unstructured":"Park J, Sk\u00e5lhegg BS (2025) Combination of PD-1\/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update. Front Immunol 16:1680838","journal-title":"Front Immunol"},{"key":"12519_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-025-01734-x","volume":"18","author":"L Huang","year":"2025","unstructured":"Huang L, Zhu H, Shi Y (2025) Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000\u20132025). J Hematol Oncol 18:107","journal-title":"J Hematol Oncol"},{"key":"12519_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"L Topalian Suzanne","year":"2015","unstructured":"Topalian Suzanne L, Drake Charles G, Pardoll Drew M (2015) Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell 27:450\u2013461","journal-title":"Cancer Cell"},{"key":"12519_CR11","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"key":"12519_CR12","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41590-024-02015-4","volume":"25","author":"S Goswami","year":"2024","unstructured":"Goswami S, Pauken KE, Wang L, Sharma P (2024) Next-generation combination approaches for immune checkpoint therapy. Nat Immunol 25:2186\u20132199","journal-title":"Nat Immunol"},{"key":"12519_CR13","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.molmed.2025.03.010","volume":"31","author":"P Verdys","year":"2025","unstructured":"Verdys P, Johansen AZ, Gupta A, Presti M, Dionisio E, Madsen DH et al (2025) Acquired resistance to immunotherapy in solid tumors. Trends Mol Med 31:1008\u20131020","journal-title":"Trends Mol Med"},{"key":"12519_CR14","doi-asserted-by":"publisher","first-page":"104426","DOI":"10.1016\/j.critrevonc.2024.104426","volume":"201","author":"W Li","year":"2024","unstructured":"Li W, Gu J, Fan H, Zhang L, Guo J, Si L (2024) Evolving cancer resistance to anti-PD-1\/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects. Crit Rev Oncol\/Hematol 201:104426","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"12519_CR15","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12943-024-02175-9","volume":"23","author":"M-Q Yang","year":"2024","unstructured":"Yang M-Q, Zhang S-L, Sun L, Huang L-T, Yu J, Zhang J-H et al (2024) Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells. Mol Cancer 23:260","journal-title":"Mol Cancer"},{"issue":"15","key":"12519_CR16","doi-asserted-by":"publisher","first-page":"7400","DOI":"10.3390\/ijms26157400","volume":"26","author":"F Li","year":"2025","unstructured":"Li F, Feng Y, Yin Z, Wang Y (2025) Mitochondrial Metabolism in T-Cell Exhaustion. Int J Mol Sci 26(15):7400","journal-title":"Int J Mol Sci"},{"key":"12519_CR17","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","volume":"21","author":"SA Vardhana","year":"2020","unstructured":"Vardhana SA, Hwee MA, Berisa M, Wells DK, Yost KE, King B et al (2020) Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol 21:1022\u20131033","journal-title":"Nat Immunol"},{"issue":"3","key":"12519_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW (2016) The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci 41(3):211\u2013218","journal-title":"Trends Biochem Sci"},{"key":"12519_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40364-024-00646-1","volume":"12","author":"H Zhang","year":"2024","unstructured":"Zhang H, Li S, Wang D, Liu S, Xiao T, Gu W et al (2024) Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment. Biomark Res 12:96","journal-title":"Biomark Res"},{"key":"12519_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41419-024-07122-6","volume":"15","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Xu R, Chen X, Lu Y, Zheng J, Lin Y et al (2024) Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment. Cell Death Dis 15:775","journal-title":"Cell Death Dis"},{"key":"12519_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.5483\/BMBRep.2024-0031","volume":"57","author":"SA Lim","year":"2024","unstructured":"Lim SA (2024) Metabolic reprogramming of the tumor microenvironment to enhance immunotherapy. BMB Rep 57:388\u2013399","journal-title":"BMB Rep"},{"key":"12519_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/bs.ircmb.2024.07.003","volume":"389","author":"S Pandey","year":"2024","unstructured":"Pandey S, Anang V, Schumacher MM (2024) Tumor microenvironment induced switch to mitochondrial metabolism promotes suppressive functions in immune cells. Int Rev cell Mol biology 389:67\u2013103","journal-title":"Int Rev cell Mol biology"},{"key":"12519_CR23","doi-asserted-by":"publisher","first-page":"116203","DOI":"10.1016\/j.biopha.2024.116203","volume":"171","author":"J-W Cui","year":"2024","unstructured":"Cui J-W, Li Y, Yang Y, Yang H-K, Dong J-M, Xiao Z-H et al (2024) Tumor immunotherapy resistance: Revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape. Biomed Pharmacother 171:116203","journal-title":"Biomed Pharmacother"},{"key":"12519_CR24","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1038\/s41467-023-40745-5","volume":"14","author":"S Hiltbrunner","year":"2023","unstructured":"Hiltbrunner S, Cords L, Kasser S, Freiberger SN, Kreutzer S, Toussaint NC et al (2023) Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype. Nat Commun 14:5154","journal-title":"Nat Commun"},{"key":"12519_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC (2023) Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell 41:421\u2013433","journal-title":"Cancer Cell"},{"key":"12519_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41420-024-01953-0","volume":"10","author":"W You","year":"2024","unstructured":"You W, Knoops K, Berendschot TTJM, Benedikter BJ, Webers CAB, Reutelingsperger CPM et al (2024) PGC-1a mediated mitochondrial biogenesis promotes recovery and survival of neuronal cells from cellular degeneration. Cell Death Discovery 10:180","journal-title":"Cell Death Discovery"},{"key":"12519_CR27","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41590-024-01896-9","volume":"25","author":"CC Zebley","year":"2024","unstructured":"Zebley CC, Zehn D, Gottschalk S, Chi H (2024) T cell dysfunction and therapeutic intervention in cancer. Nat Immunol 25:1344\u20131354","journal-title":"Nat Immunol"},{"issue":"9","key":"12519_CR28","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.3390\/cancers14092291","volume":"14","author":"RA Castillo-Rodr\u00edguez","year":"2022","unstructured":"Castillo-Rodr\u00edguez RA, Trejo-Sol\u00eds C, Cabrera-Cano A, G\u00f3mez-Manzo S, D\u00e1vila-Borja VM (2022) Hypoxia as a Modulator of Inflammation and Immune Response in Cancer. Cancers (Basel) 14(9):2291","journal-title":"Cancers (Basel)"},{"key":"12519_CR29","doi-asserted-by":"publisher","first-page":"114646","DOI":"10.1016\/j.biopha.2023.114646","volume":"162","author":"K Mortezaee","year":"2023","unstructured":"Mortezaee K, Majidpoor J, Kharazinejad E (2023) The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy. Biomed Pharmacother 162:114646","journal-title":"Biomed Pharmacother"},{"key":"12519_CR30","doi-asserted-by":"publisher","first-page":"1646292","DOI":"10.3389\/fimmu.2025.1646292","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Song S (2025) Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach. Front Immunol 16:1646292","journal-title":"Front Immunol"},{"key":"12519_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s13402-026-01186-6","volume":"49","author":"X Wang","year":"2026","unstructured":"Wang X, Xiong D, Cui S, Duan B, Ding G, Huang Y et al (2026) Lactate signaling and immune suppression in tumors: mechanisms and therapeutic implications. Cell Oncol 49:75","journal-title":"Cell Oncol"},{"key":"12519_CR32","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s41590-024-01999-3","volume":"25","author":"RM Peralta","year":"2024","unstructured":"Peralta RM, Xie B, Lontos K, Nieves-Rosado H, Spahr K, Joshi S et al (2024) Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism. Nat Immunol 25:2297\u20132307","journal-title":"Nat Immunol"},{"key":"12519_CR33","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.1038\/s41467-023-42634-3","volume":"14","author":"H Wu","year":"2023","unstructured":"Wu H, Zhao X, Hochrein SM, Eckstein M, Gubert GF, Kn\u00f6pper K et al (2023) Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1\u03b1-mediated glycolytic reprogramming. Nat Commun 14:6858","journal-title":"Nat Commun"},{"key":"12519_CR34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s40164-025-00719-3","volume":"14","author":"X Ji","year":"2025","unstructured":"Ji X, Xia L (2025) Lactate and lactylation in cancer: drivers of immune suppression and microenvironmental reprogramming. Experimental Hematol Oncol 14:128","journal-title":"Experimental Hematol Oncol"},{"issue":"38","key":"12519_CR35","doi-asserted-by":"publisher","first-page":"eabd2712","DOI":"10.1126\/sciadv.abd2712","volume":"6","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Wang Q, Strauss L, Boussiotis VA (2020) Revisiting the PD-1 pathway. Sci Adv 6(38):eabd2712","journal-title":"Sci Adv"},{"issue":"2","key":"12519_CR36","doi-asserted-by":"publisher","first-page":"e220007","DOI":"10.20900\/immunometab20220007","volume":"4","author":"VA Boussiotis","year":"2022","unstructured":"Boussiotis VA, Patsoukis N (2022) Effects of PD-1 Signaling on Immunometabolic Reprogramming. Immunometabolism 4(2):e220007","journal-title":"Immunometabolism"},{"key":"12519_CR37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15:486\u2013499","journal-title":"Nat Rev Immunol"},{"key":"12519_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W et al (2024) Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer 23:108","journal-title":"Mol Cancer"},{"key":"12519_CR39","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41416-022-02084-y","volume":"128","author":"Y Wang","year":"2023","unstructured":"Wang Y, Du J, Gao Z, Sun H, Mei M, Wang Y et al (2023) Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer 128:1196\u20131207","journal-title":"Br J Cancer"},{"key":"12519_CR40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"J-H Cha","year":"2019","unstructured":"Cha J-H, Chan L-C, Li C-W, Hsu JL, Hung M-C (2019) Mechanisms Controlling PD-L1 Expression in Cancer. Mol Cell 76:359\u2013370","journal-title":"Mol Cell"},{"key":"12519_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18:153\u2013167","journal-title":"Nat Rev Immunol"},{"key":"12519_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","volume":"8","author":"J-Y Sun","year":"2020","unstructured":"Sun J-Y, Zhang D, Wu S, Xu M, Zhou X, Lu X-J et al (2020) Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res 8:35","journal-title":"Biomark Res"},{"key":"12519_CR43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-immunol-101819-024752","volume":"42","author":"HN Bell","year":"2024","unstructured":"Bell HN, Zou W (2024) Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance. Annu Rev Immunol 42:521\u2013550","journal-title":"Annu Rev Immunol"},{"key":"12519_CR44","doi-asserted-by":"publisher","first-page":"1512509","DOI":"10.3389\/fimmu.2025.1512509","volume":"16","author":"X Han","year":"2025","unstructured":"Han X, Zhang J, Li W, Huang X, Wang X, Wang B et al (2025) The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies. Front Immunol 16:1512509","journal-title":"Front Immunol"},{"key":"12519_CR45","doi-asserted-by":"publisher","first-page":"844866","DOI":"10.3389\/fimmu.2022.844866","volume":"13","author":"BC Taylor","year":"2022","unstructured":"Taylor BC, Balko JM (2022) Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response. Front Immunol 13:844866","journal-title":"Front Immunol"},{"key":"12519_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10238-023-01274-z","volume":"24","author":"K Mortezaee","year":"2024","unstructured":"Mortezaee K (2024) WNT\/\u03b2-catenin regulatory roles on PD-(L)1 and immunotherapy responses. Clin Experimental Med 24:15","journal-title":"Clin Experimental Med"},{"key":"12519_CR47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41577-021-00563-6","volume":"22","author":"X Zhao","year":"2022","unstructured":"Zhao X, Shan Q, Xue H-H (2022) TCF1 in T cell immunity: a broadened frontier. Nat Rev Immunol 22:147\u2013157","journal-title":"Nat Rev Immunol"},{"key":"12519_CR48","doi-asserted-by":"publisher","first-page":"759015","DOI":"10.3389\/fonc.2021.759015","volume":"11","author":"Y Xu","year":"2021","unstructured":"Xu Y, He L, Fu Q, Hu J (2021) Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints. Front Oncol 11:759015","journal-title":"Front Oncol"},{"key":"12519_CR49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12929-025-01186-y","volume":"32","author":"S Sarkar","year":"2025","unstructured":"Sarkar S, Chang CI, Jean J, Wu MJ (2025) TCA cycle-derived oncometabolites in cancer and the immune microenvironment. J Biomed Sci 32:87","journal-title":"J Biomed Sci"},{"key":"12519_CR50","doi-asserted-by":"publisher","first-page":"1688699","DOI":"10.3389\/fimmu.2025.1688699","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, He J, Ding G, Tang Y, Wang Q (2025) Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies. Front Immunol 16:1688699","journal-title":"Front Immunol"},{"key":"12519_CR51","doi-asserted-by":"publisher","first-page":"352","DOI":"10.20517\/jtgg.2025.90","volume":"9","author":"V Karri","year":"2025","unstructured":"Karri V, Dalia SM (2025) Persistent IFN-\u03b3 signaling in acquired resistance to PD-(L)1 blockade in NSCLC. J Translational Genet Genomics 9:352\u2013358","journal-title":"J Translational Genet Genomics"},{"key":"12519_CR52","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fcell.2020.00672","volume":"8","author":"Q Lei","year":"2020","unstructured":"Lei Q, Wang D, Sun K, Wang L, Zhang Y (2020) Resistance Mechanisms of Anti-PD1\/PDL1 Therapy in Solid Tumors. Front Cell Dev Biol 8:672","journal-title":"Front Cell Dev Biol"},{"key":"12519_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"NE Scharping","year":"2021","unstructured":"Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL et al (2021) Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol 22:205\u2013215","journal-title":"Nat Immunol"},{"key":"12519_CR54","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J et al (2017) Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov 7:264\u2013276","journal-title":"Cancer Discov"},{"key":"12519_CR55","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13578-023-01073-9","volume":"13","author":"B Wang","year":"2023","unstructured":"Wang B, Han Y, Zhang Y, Zhao Q, Wang H, Wei J et al (2023) Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms. Cell Bioscience 13:120","journal-title":"Cell Bioscience"},{"key":"12519_CR56","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1186\/s12967-025-07069-y","volume":"23","author":"Y Wang","year":"2025","unstructured":"Wang Y, Chen W, Wang Z, Cai S, Zhao X, Jin J et al (2025) Deciphering metabolic reprogramming of immune cells within the tumor microenvironment. J Translational Med 23:1055","journal-title":"J Translational Med"},{"key":"12519_CR57","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12863-022-01032-2","volume":"23","author":"GC Cavalcante","year":"2022","unstructured":"Cavalcante GC, Ribeiro-dos-Santos \u00c2, de Ara\u00fajo GS (2022) Mitochondria in tumour progression: a network of mtDNA variants in different types of cancer. BMC Genomic Data 23:16","journal-title":"BMC Genomic Data"},{"key":"12519_CR58","doi-asserted-by":"publisher","first-page":"27640","DOI":"10.34172\/bi.2023.27640","volume":"14","author":"Z Mazloumi","year":"2024","unstructured":"Mazloumi Z, Rafat A, Dizaji Asl K, Karimipour M, Shanehbandi D, Talebi M et al (2024) Telomerase and mitochondria inhibition promote apoptosis and TET2 and ANMT3a expression in triple negative breast cancer cell lines. BioImpacts: BI 14:27640","journal-title":"BioImpacts: BI"},{"key":"12519_CR59","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg O (1956) On the origin of cancer cells. Science 123:309\u2013314","journal-title":"Science"},{"key":"12519_CR60","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-025-02311-x","volume":"10","author":"H Du","year":"2025","unstructured":"Du H, Xu T, Yu S, Wu S, Zhang J (2025) Mitochondrial metabolism and cancer therapeutic innovation. Signal Transduct Target Therapy 10:245","journal-title":"Signal Transduct Target Therapy"},{"key":"12519_CR61","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","volume":"23","author":"M Tufail","year":"2024","unstructured":"Tufail M, Jiang C-H, Li N (2024) Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol Cancer 23:203","journal-title":"Mol Cancer"},{"key":"12519_CR62","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/s41418-022-01022-y","volume":"29","author":"L Sainero-Alcolado","year":"2022","unstructured":"Sainero-Alcolado L, Lia\u00f1o-Pons J, Ruiz-P\u00e9rez MV, Arsenian-Henriksson M (2022) Targeting mitochondrial metabolism for precision medicine in cancer. Cell Death Differ 29:1304\u20131317","journal-title":"Cell Death Differ"},{"key":"12519_CR63","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","volume":"24","author":"A Luengo","year":"2017","unstructured":"Luengo A, Gui DY, Vander Heiden MG (2017) Targeting Metabolism for Cancer Therapy. Cell Chem Biol 24:1161\u20131180","journal-title":"Cell Chem Biol"},{"key":"12519_CR64","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12929-022-00859-2","volume":"29","author":"CL Kuo","year":"2022","unstructured":"Kuo CL, Ponneri Babuharisankar A, Lin YC, Lien HW, Lo YK, Chou HY et al (2022) Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend? J Biomed Sci 29:74","journal-title":"J Biomed Sci"},{"key":"12519_CR65","doi-asserted-by":"publisher","first-page":"114","DOI":"10.15698\/cst2020.06.221","volume":"4","author":"D Grasso","year":"2020","unstructured":"Grasso D, Zampieri LX, Capel\u00f4a T, Van de Velde JA, Sonveaux P (2020) Mitochondria in cancer. Cell Stress 4:114\u2013146","journal-title":"Cell Stress"},{"key":"12519_CR66","doi-asserted-by":"crossref","unstructured":"Musicco C, Signorile A, Pesce V, Loguercio Polosa P, Cormio A (2023) Mitochondria Deregulations in Cancer Offer Several Potential Targets of Therapeutic Interventions. Int J Mol Sci. ;24","DOI":"10.3390\/ijms241310420"},{"key":"12519_CR67","doi-asserted-by":"publisher","first-page":"176106","DOI":"10.1016\/j.ejphar.2023.176106","volume":"960","author":"S Hossenipour Khodaei","year":"2023","unstructured":"Hossenipour Khodaei S, Sabetnam S, Nozad Charoudeh H, Dizaji Asl K, Rafat A, Mazloumi Z (2023) The effect of mitochondria inhibition on natural killer cells cytotoxicity in triple-negative breast cancer cells. Eur J Pharmacol 960:176106","journal-title":"Eur J Pharmacol"},{"key":"12519_CR68","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cmet.2020.06.019","volume":"32","author":"K Vasan","year":"2020","unstructured":"Vasan K, Werner M, Chandel NS (2020) Mitochondrial Metabolism as a Target for Cancer Therapy. Cell Metabol 32:341\u2013352","journal-title":"Cell Metabol"},{"key":"12519_CR69","doi-asserted-by":"crossref","unstructured":"Zhang M, Liu J, Xu G, Li H, Sun Y, Peng X (2026) Mitochondria transfer: intercellular communication and tumor microenvironment dynamics. Cell Communication Signal","DOI":"10.1186\/s12964-026-02820-4"},{"key":"12519_CR70","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13046-024-03069-w","volume":"43","author":"F Guan","year":"2024","unstructured":"Guan F, Wu X, Zhou J, Lin Y, He Y, Fan C et al (2024) Mitochondrial transfer in tunneling nanotubes\u2014a new target for cancer therapy. J Experimental Clin Cancer Res 43:147","journal-title":"J Experimental Clin Cancer Res"},{"issue":"1","key":"12519_CR71","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13287-026-05011-7","volume":"17","author":"FV Nezamdoust","year":"2026","unstructured":"Nezamdoust FV, Nezhad-Mokhtari P, Mirzaahmadi B, Mazloumi Z, Kangari P, Rahbarghazi R (2026) Application of dendritic cell extracellular vesicles as a valid nanoparticle platform for cancer therapies: a narrative review. Stem Cell Res Ther 17(1):206","journal-title":"Stem Cell Res Ther"},{"key":"12519_CR72","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12860-016-0104-x","volume":"17","author":"C Cammann","year":"2016","unstructured":"Cammann C, Rath A, Reichl U, Lingel H, Brunner-Weinzierl M, Simeoni L et al (2016) Early changes in the metabolic profile of activated CD8\u2009+\u2009T cells. BMC Cell Biol 17:28","journal-title":"BMC Cell Biol"},{"key":"12519_CR73","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41590-020-0793-3","volume":"21","author":"Y-R Yu","year":"2020","unstructured":"Yu Y-R, Imrichova H, Wang H, Chao T, Xiao Z, Gao M et al (2020) Disturbed mitochondrial dynamics in CD8\u2009+\u2009TILs reinforce T cell exhaustion. Nat Immunol 21:1540\u20131551","journal-title":"Nat Immunol"},{"key":"12519_CR74","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1182\/bloodadvances.2024014822","volume":"9","author":"W Gamal","year":"2025","unstructured":"Gamal W, Goedhart NB, Simon-Molas H, Mediavilla-Varela M, Uriepero-Palma A, Peters FS et al (2025) Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model. Blood Adv 9:2511\u20132529","journal-title":"Blood Adv"},{"key":"12519_CR75","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s40425-019-0628-7","volume":"7","author":"J Ogando","year":"2019","unstructured":"Ogando J, S\u00e1ez ME, Santos J, Nuevo-Tapioles C, Gut M, Esteve-Codina A et al (2019) PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8(+) T lymphocytes. J Immunother Cancer 7:151","journal-title":"J Immunother Cancer"},{"key":"12519_CR76","doi-asserted-by":"publisher","first-page":"eadf9522","DOI":"10.1126\/sciadv.adf9522","volume":"9","author":"C Chen","year":"2023","unstructured":"Chen C, Zheng H, Horwitz EM, Ando S, Araki K, Zhao P et al (2023) Mitochondrial metabolic flexibility is critical for CD8(+) T cell antitumor immunity. Sci Adv 9:eadf9522","journal-title":"Sci Adv"},{"issue":"2","key":"12519_CR77","doi-asserted-by":"publisher","first-page":"e138519","DOI":"10.1172\/JCI138519","volume":"131","author":"SL Pompura","year":"2021","unstructured":"Pompura SL, Wagner A, Kitz A, LaPerche J, Yosef N, Dominguez-Villar M, Hafler DA (2021) Oleic acid restores suppressive defects in tissue-resident FOXP3 Tregs from patients with multiple sclerosis. J Clin Invest 131(2):e138519","journal-title":"J Clin Invest"},{"key":"12519_CR78","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/s41388-025-03458-1","volume":"44","author":"J Saravia","year":"2025","unstructured":"Saravia J, Chi H (2025) Immunometabolism of regulatory T cells in cancer. Oncogene 44:2011\u20132024","journal-title":"Oncogene"},{"key":"12519_CR79","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.7150\/thno.105276","volume":"15","author":"H Wang","year":"2025","unstructured":"Wang H, Zhou F, Qin W, Yang Y, Li X, Liu R (2025) Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies. Theranostics 15:2159\u20132184","journal-title":"Theranostics"},{"key":"12519_CR80","doi-asserted-by":"publisher","first-page":"115332","DOI":"10.1016\/j.ejca.2025.115332","volume":"220","author":"AF Karimova","year":"2025","unstructured":"Karimova AF, Khalitova AR, Suezov R, Markov N, Mukhamedshina Y, Rizvanov AA et al (2025) Immunometabolism of tumor-associated macrophages: A therapeutic perspective. Eur J Cancer 220:115332","journal-title":"Eur J Cancer"},{"key":"12519_CR81","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12944-023-01807-1","volume":"22","author":"X Qiao","year":"2023","unstructured":"Qiao X, Hu Z, Xiong F, Yang Y, Peng C, Wang D et al (2023) Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy. Lipids Health Dis 22:45","journal-title":"Lipids Health Dis"},{"key":"12519_CR82","doi-asserted-by":"publisher","first-page":"104032","DOI":"10.1016\/j.redox.2026.104032","volume":"90","author":"B Chen","year":"2026","unstructured":"Chen B, Mayer JU (2026) Emerging frontiers in the mitochondrial regulation of dendritic cell biology. Redox Biol 90:104032","journal-title":"Redox Biol"},{"key":"12519_CR83","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3892\/mmr.2024.13413","volume":"31","author":"Y Zeng","year":"2025","unstructured":"Zeng Y, Huang Y, Tan Q, Peng L, Wang J, Tong F et al (2025) Influence of lactate in resistance to anti\u2013PD\u20131\/PD\u2013L1 therapy: Mechanisms and clinical applications (Review). Mol Med Rep 31:48","journal-title":"Mol Med Rep"},{"key":"12519_CR84","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1038\/s41467-021-25715-z","volume":"12","author":"E Littwitz-Salomon","year":"2021","unstructured":"Littwitz-Salomon E, Moreira D, Frost JN, Choi C, Liou KT, Ahern DK et al (2021) Metabolic requirements of NK cells during the acute response against retroviral infection. Nat Commun 12:5376","journal-title":"Nat Commun"},{"key":"12519_CR85","doi-asserted-by":"publisher","first-page":"e00020","DOI":"10.1097\/IN9.0000000000000020","volume":"5","author":"H Sohn","year":"2023","unstructured":"Sohn H, Cooper MA (2023) Metabolic regulation of NK cell function: implications for immunotherapy. Immunometabolism (Cobham) 5:e00020","journal-title":"Immunometabolism (Cobham)"},{"key":"12519_CR86","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.7150\/ijbs.125206","volume":"22","author":"J Ai","year":"2026","unstructured":"Ai J, Du Y, Xue Q, Peng W, Zhou Q (2026) Metabolic Checkpoints in CD8(+) T Cells within the Tumor Microenvironment: A Comprehensive Review and Emerging Insights. Int J Biol Sci 22:1950\u20131973","journal-title":"Int J Biol Sci"},{"issue":"1","key":"12519_CR87","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.molmed.2025.04.004","volume":"32","author":"T De Verhezen","year":"2026","unstructured":"Verhezen T, Wouters A, Smits E, De Waele J (2026) Powering immunity: mitochondrial dynamics in natural killer cells. Trends Mol Med 32(1):49\u201364","journal-title":"Trends Mol Med"},{"key":"12519_CR88","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41556-018-0124-1","volume":"20","author":"JB Spinelli","year":"2018","unstructured":"Spinelli JB, Haigis MC (2018) The multifaceted contributions of mitochondria to cellular metabolism. Nat Cell Biol 20:745\u2013754","journal-title":"Nat Cell Biol"},{"issue":"1","key":"12519_CR89","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cmet.2020.10.021","volume":"33","author":"H Lv","year":"2021","unstructured":"Lv H, Lv G, Chen C, Zong Q, Jiang G, Ye D, Cui X, He Y, Xiang W, Han Q, Tang L, Yang W, Wang H (2021) NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion. Cell Metab 33(1):110\u2013127e5","journal-title":"Cell Metab"},{"key":"12519_CR90","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","volume":"9","author":"KG de la Cruz-L\u00f3pez","year":"2019","unstructured":"de la Cruz-L\u00f3pez KG, Castro-Mu\u00f1oz LJ, Reyes-Hern\u00e1ndez DO, Garc\u00eda-Carranc\u00e1 A, Manzo-Merino J (2019) Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches. Front Oncol 9:1143","journal-title":"Front Oncol"},{"key":"12519_CR91","doi-asserted-by":"crossref","unstructured":"Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y et al (2022) Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. ;40(2):201-218.e9","DOI":"10.1016\/j.ccell.2022.01.001"},{"key":"12519_CR92","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s11684-025-1148-0","volume":"19","author":"L Song","year":"2025","unstructured":"Song L, Sun L, Chen S, Lan P (2025) Lactate and lactylation in tumor immunity. Front Med 19:697\u2013720","journal-title":"Front Med"},{"key":"12519_CR93","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12943-025-02477-6","volume":"24","author":"Y-T Liu","year":"2025","unstructured":"Liu Y-T, Wang Y-L, Wang S, Li J-J, He W, Fan X-J et al (2025) Turning cold tumors into hot tumors to ignite immunotherapy. Mol Cancer 24:254","journal-title":"Mol Cancer"},{"key":"12519_CR94","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1038\/s41467-022-32521-8","volume":"13","author":"Q Feng","year":"2022","unstructured":"Feng Q, Liu Z, Yu X, Huang T, Chen J, Wang J et al (2022) Lactate increases stemness of CD8\u2009+\u2009T cells to augment anti-tumor immunity. Nat Commun 13:4981","journal-title":"Nat Commun"},{"key":"12519_CR95","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cmet.2025.12.002","volume":"38","author":"H Tong","year":"2026","unstructured":"Tong H, Jiang Z, Song L, Tan K, Yin X, He C et al (2026) Dual impacts of serine\/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation. Cell Metabol 38:247","journal-title":"Cell Metabol"},{"key":"12519_CR96","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H et al (2011) Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of \u03b1-Ketoglutarate-Dependent Dioxygenases. Cancer Cell 19:17\u201330","journal-title":"Cancer Cell"},{"key":"12519_CR97","first-page":"2500","volume":"109","author":"K Hammon","year":"2024","unstructured":"Hammon K, Renner K, Althammer M, Voll F, Babl N, Decking SM et al (2024) D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells. Haematologica 109:2500\u20132514","journal-title":"Haematologica"},{"issue":"7","key":"12519_CR98","doi-asserted-by":"publisher","first-page":"e174600","DOI":"10.1172\/jci.insight.174600","volume":"10","author":"Y Yang","year":"2025","unstructured":"Yang Y, Li X, Liu F, Ma M, Yang Y, Ruan C, Lu Y, Li X, Wang X, Shi Y, Zhang Z, Wang H, Cheng Z, Wu D (2025) Immunometabolite L-2-HG promotes epigenetic modification of exhausted T cells and improves antitumor immunity. JCI Insight 10(7):e174600","journal-title":"JCI Insight"},{"key":"12519_CR99","doi-asserted-by":"publisher","first-page":"e24454","DOI":"10.1016\/j.heliyon.2024.e24454","volume":"10","author":"M Cai","year":"2024","unstructured":"Cai M, Zhao J, Ding Q, Wei J (2024) Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity. Heliyon 10:e24454","journal-title":"Heliyon"},{"key":"12519_CR100","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202511.1296.v1","volume-title":"Reactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma","author":"M Hashim","year":"2025","unstructured":"Hashim M, Timelthaler G, Kirchhofer D, Kudlacek B, Mosleh B, Sinn K et al (2025) Reactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma. Preprints, Preprints"},{"key":"12519_CR101","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-026-01780-z","volume":"19","author":"J Li","year":"2026","unstructured":"Li J, Huang C, Tang P, Wu R, Wu Q, Zhang C (2026) The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications. J Hematol Oncol 19:16","journal-title":"J Hematol Oncol"},{"key":"12519_CR102","doi-asserted-by":"publisher","first-page":"117482","DOI":"10.1016\/j.biopha.2024.117482","volume":"180","author":"N Liu","year":"2024","unstructured":"Liu N, Li J, Dai H, Liang X, Fan H (2024) Involvement of SIRT1-mediated cellular immune response in cancer. Biomed Pharmacother 180:117482","journal-title":"Biomed Pharmacother"},{"key":"12519_CR103","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN et al (2015) PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 6:6692","journal-title":"Nat Commun"},{"key":"12519_CR104","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD et al (2015) Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 162:1229\u20131241","journal-title":"Cell"},{"key":"12519_CR105","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","volume":"45","author":"B Bengsch","year":"2016","unstructured":"Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J et al (2016) Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. Immunity 45:358\u2013373","journal-title":"Immunity"},{"issue":"Pt 3","key":"12519_CR106","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1042\/bj3480607","volume":"348","author":"MR Owen","year":"2000","unstructured":"Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348(Pt 3):607\u2013614","journal-title":"Biochem J"},{"key":"12519_CR107","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/2326-6066.CIR-16-0103","volume":"5","author":"NE Scharping","year":"2017","unstructured":"Scharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM (2017) Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. Cancer Immunol Res 5:9\u201316","journal-title":"Cancer Immunol Res"},{"key":"12519_CR108","doi-asserted-by":"publisher","first-page":"e02242","DOI":"10.7554\/eLife.02242","volume":"3","author":"WW Wheaton","year":"2014","unstructured":"Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E et al (2014) Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 3:e02242","journal-title":"eLife"},{"key":"12519_CR109","doi-asserted-by":"publisher","first-page":"864225","DOI":"10.3389\/fimmu.2022.864225","volume":"13","author":"R Chao","year":"2022","unstructured":"Chao R, Nishida M, Yamashita N, Tokumasu M, Zhao W, Kudo I et al (2022) Nutrient Condition in the Microenvironment Determines Essential Metabolisms of CD8(+) T Cells for Enhanced IFN\u03b3 Production by Metformin. Front Immunol 13:864225","journal-title":"Front Immunol"},{"key":"12519_CR110","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","volume":"108","author":"G Zhou","year":"2001","unstructured":"Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167\u20131174","journal-title":"J Clin Invest"},{"key":"12519_CR111","doi-asserted-by":"publisher","first-page":"108015","DOI":"10.1016\/j.phrs.2025.108015","volume":"222","author":"QC Ton Nu","year":"2025","unstructured":"Ton Nu QC, Park P-H (2025) Metabolic modulation of CD8\u207a T cells by metformin: A promising adjuvant strategy for CD8\u207a T Cell-Based Immunotherapies. Pharmacol Res 222:108015","journal-title":"Pharmacol Res"},{"key":"12519_CR112","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.4049\/jimmunol.1901213","volume":"204","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Li F, Tian Y, Cao L, Gao Q, Zhang C et al (2020) Metformin Enhances the Antitumor Activity of CD8(+) T Lymphocytes via the AMPK-miR-107-Eomes-PD-1 Pathway. J Immunol 204:2575\u20132588","journal-title":"J Immunol"},{"key":"12519_CR113","doi-asserted-by":"publisher","first-page":"780200","DOI":"10.3389\/fmolb.2022.780200","volume":"9","author":"Z Wang","year":"2022","unstructured":"Wang Z, Lu C, Zhang K, Lin C, Wu F, Tang X, Wu D, Dou Y, Han R, Wang Y, Hou C, Ouyang Q, Feng M, He Y, Li L (2022) Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination. Front Mol Biosci 9:780200","journal-title":"Front Mol Biosci"},{"key":"12519_CR114","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.jtho.2023.07.020","volume":"18","author":"A Li","year":"2023","unstructured":"Li A, Wang Y, Yu Z, Tan Z, He L, Fu S et al (2023) STK11\/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING\/Type I Interferon\/CD8\u2009+\u2009T-Cell Dysfunction in NSCLC. J Thorac Oncol 18:1714\u20131730","journal-title":"J Thorac Oncol"},{"key":"12519_CR115","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K, Cohen S, Liu D, Parikh A et al (2024) Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer 24:498\u2013512","journal-title":"Nat Rev Cancer"},{"key":"12519_CR116","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41392-023-01320-y","volume":"8","author":"K Wang","year":"2023","unstructured":"Wang K, Zhang Y, Chen Z-N (2023) Metabolic interaction: tumor-derived lactate inhibiting CD8\u2009+\u2009T cell cytotoxicity in a novel route. Signal Transduct Target Therapy 8:52","journal-title":"Signal Transduct Target Therapy"},{"key":"12519_CR117","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A et al (2016) LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab 24:657\u2013671","journal-title":"Cell Metab"},{"issue":"9","key":"12519_CR118","doi-asserted-by":"publisher","first-page":"e012230","DOI":"10.1136\/jitc-2025-012230","volume":"13","author":"S Liu","year":"2025","unstructured":"Liu S, Pan Y, Liu W, Bu X, Shao R, Wang Q, Wu J, Wu C, Hu W, Xu J, Wu C, Jiang J (2025) Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma. J Immunother Cancer 13(9):e012230","journal-title":"J Immunother Cancer"},{"issue":"4","key":"12519_CR119","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/cancers11040450","volume":"11","author":"S Daneshmandi","year":"2019","unstructured":"Daneshmandi S, Wegiel B, Seth P (2019) Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma. Cancers (Basel) 11(4):450","journal-title":"Cancers (Basel)"},{"key":"12519_CR120","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s11684-023-1025-7","volume":"17","author":"L Liao","year":"2023","unstructured":"Liao L, Xu H, Zhao Y, Zheng X (2023) Metabolic interventions combined with CTLA-4 and PD-1\/PD-L1 blockade for the treatment of tumors: mechanisms and strategies. Front Med 17:805\u2013822","journal-title":"Front Med"},{"key":"12519_CR121","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12943-025-02460-1","volume":"24","author":"H Zhang","year":"2025","unstructured":"Zhang H, Fan J, Kong D, Sun Y, Zhang Q, Xiang R et al (2025) Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy. Mol Cancer 24:249","journal-title":"Mol Cancer"},{"key":"12519_CR122","doi-asserted-by":"publisher","first-page":"114324","DOI":"10.1016\/j.jconrel.2025.114324","volume":"388","author":"D Yan","year":"2025","unstructured":"Yan D, Yi W, Wu T, Hu S, Ding Y, Qian X et al (2025) Dual-sensitization nanoformulation combining glutamine metabolism inhibition and Fas\/FasL activation for enhanced colorectal cancer immunotherapy. J Controlled Release 388:114324","journal-title":"J Controlled Release"},{"key":"12519_CR123","doi-asserted-by":"publisher","first-page":"1632446","DOI":"10.3389\/fphar.2025.1632446","volume":"16","author":"RM Al Al-Zoubi","year":"2025","unstructured":"Al-Zoubi RM, Elaarag M, Al-Qudimat AR, Al-Hurani EA, Fares ZE, Farhan A, Al-Zoubi SR, Khan A, Agouni A, Shkoor M, Bawadi H, Zakaria ZZ, Al Zoubi M, Alrumaihi K (2025) IDO and TDO inhibitors in cancer immunotherapy: mechanisms, clinical development, and future directions. Front Pharmacol 16:1632446","journal-title":"Front Pharmacol"},{"key":"12519_CR124","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/cancers14071850","volume":"14","author":"N Mabrouk","year":"2022","unstructured":"Mabrouk N, Lecoeur B, Bettaieb A, Paul C, V\u00e9gran F (2022) Impact of Lipid Metabolism on Antitumor Immune Response. Cancers 14:1850","journal-title":"Cancers"},{"key":"12519_CR125","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41423-024-01224-z","volume":"21","author":"Y Tang","year":"2024","unstructured":"Tang Y, Chen Z, Zuo Q, Kang Y (2024) Regulation of CD8\u2009+\u2009T cells by lipid metabolism in cancer progression. Cell Mol Immunol 21:1215\u20131230","journal-title":"Cell Mol Immunol"},{"key":"12519_CR126","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-15-0036","volume":"3","author":"F Hossain","year":"2015","unstructured":"Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reiss K et al (2015) Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Cancer Immunol Res 3:1236\u20131247","journal-title":"Cancer Immunol Res"},{"key":"12519_CR127","doi-asserted-by":"publisher","first-page":"109516","DOI":"10.1016\/j.celrep.2021.109516","volume":"36","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang F, Wang L, Qiu S, Yao Y, Yan C et al (2021) NAD+ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells. Cell Rep 36:109516","journal-title":"Cell Rep"},{"key":"12519_CR128","first-page":"167","volume":"16","author":"E Elayeh","year":"2025","unstructured":"Elayeh E, Aleidi SM, Aboud O, Semreen MH, Bustanji YK, Dahabiyeh LA (2025) Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC - Insights From Genomics, Proteomics, and Metabolomics. Lung Cancer (Auckland NZ) 16:167\u2013198","journal-title":"Lung Cancer (Auckland NZ)"},{"key":"12519_CR129","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/bs.ai.2019.08.004","volume":"144","author":"X Ren","year":"2019","unstructured":"Ren X, Zhang Z (2019) Understanding tumor-infiltrating lymphocytes by single cell RNA sequencing. Adv Immunol 144:217\u2013245","journal-title":"Adv Immunol"},{"key":"12519_CR130","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12943-025-02400-z","volume":"24","author":"K Mandal","year":"2025","unstructured":"Mandal K, Barik GK, Santra MK (2025) Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions. Mol Cancer 24:246","journal-title":"Mol Cancer"},{"key":"12519_CR131","doi-asserted-by":"publisher","first-page":"1688995","DOI":"10.3389\/fimmu.2025.1688995","volume":"16","author":"T Frlic","year":"2025","unstructured":"Frlic T, Pavlin M (2025) Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy. Front Immunol 16:1688995","journal-title":"Front Immunol"},{"issue":"12","key":"12519_CR132","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.3390\/pharmaceutics17121520","volume":"17","author":"AW Song","year":"2025","unstructured":"Song AW, Song X (2025) Rewiring T Cell Metabolism to Enhance CAR T Cell Function in Solid Tumor Microenvironments. Pharmaceutics 17(12):1520","journal-title":"Pharmaceutics"},{"key":"12519_CR133","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.it.2025.07.014","volume":"46","author":"EG Norton","year":"2025","unstructured":"Norton EG, Chapman NM, Chi H (2025) Mitochondria and lysosomes in T cell immunometabolism. Trends Immunol 46:635\u2013651","journal-title":"Trends Immunol"},{"key":"12519_CR134","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41419-024-07015-8","volume":"15","author":"S Tang","year":"2024","unstructured":"Tang S, Fu\u00df A, Fattahi Z, Culmsee C (2024) Drp1 depletion protects against ferroptotic cell death by preserving mitochondrial integrity and redox homeostasis. Cell Death Dis 15:626","journal-title":"Cell Death Dis"},{"key":"12519_CR135","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1038\/s41590-024-01985-9","volume":"25","author":"D Raychaudhuri","year":"2024","unstructured":"Raychaudhuri D, Singh P, Chakraborty B, Hennessey M, Tannir AJ, Byregowda S et al (2024) Histone lactylation drives CD8\u2009+\u2009T cell metabolism and function. Nat Immunol 25:2140\u20132151","journal-title":"Nat Immunol"},{"key":"12519_CR136","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40779-023-00496-2","volume":"10","author":"D Xiong","year":"2023","unstructured":"Xiong D, Zhang L, Sun Z-J (2023) Targeting the epigenome to reinvigorate T cells for cancer immunotherapy. Military Med Res 10:59","journal-title":"Military Med Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12519-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12519-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12519-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:03:12Z","timestamp":1786017792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12519-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12519"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12519-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There is no conflict of interest.","order":1,"name":"Ethics","label":"Declaration of Competing Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1350"}}